SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Enthusiasm surrounds Weedcoin, with community members actively promoting its vision and encouraging others to get behind it. The coin is drawing attention with some users noting it's trending on platforms like UpDog. Community members are pointing to links for the coin's website, Telegram and X (Twitter) accounts.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as community members rally around the tokenization of Satoshi Nakamoto's legacy, calling it the 'Bitcoin of memes'. The community highlights its strong organic growth, timeless narrative, and potential for mass adoption, suggesting it represents the ethos of the entire crypto industry. Some users mention the recent two year anniversary and the potential for innovative NFTs.

NextEra Energy, Inc. engages in the provision of renewable energy. It operates through the following segments: FPL and NEER. The FPL segment involves the generation, transmission, distribution, and sale of electric energy in Florida. The NEER segment produces electricity from clean and renewable sources, including wind and solar. The company was founded on December 28, 1925 and is headquartered in Juno Beach, FL.

NextEra Energy Inc

NEE is trending as investors assess its prospects amid a mixed landscape of options activity and analyst ratings. The community is focused on its clean energy initiatives, dividend payouts, and potential for growth in a sector facing rising power demand.  Some are also discussing its relationship with $NEP and potential impact on future results.

Annaly Capital Management, Inc. engages in the investment and financing of residential and commercial assets. It operates through the following investment groups: Agency, Residential Credit, and Mortgage Servicing Rights. The Agency group invests in agency mortgage-backed securities. The Residential Credit group involves non-agency residential mortgage assets within securitized products and whole loan markets. The Mortgage Servicing Rights group provides the right to service residential mortgage loans in exchange for a portion of the interest payments made on the loans. The company was founded by Michael A. J. Farrell and Wellington Jamie Denahan-Norris on November 25, 1996 and is headquartered in New York, NY.

Annaly Capital Management Inc

Annaly Capital ($NLY) is trending due to discussions around its high dividend yield and potential benefits from future interest rate cuts, sparking both bullish sentiment and concerns about dividend sustainability. Community members are actively debating the REIT's valuation, balance sheet, and sensitivity to interest rate movements, particularly in light of recent news and analysis pieces. Options activity is elevated, and some analysts are setting price targets above the current trading range.

Hydrex is the MetaDEX & Liquidity Infrastructure purpose-built for Base. By combining automated strategies, liquid-backed tokenomics, and Base's powerful distribution channels, Hydrex removes the barriers to yield. It's designed as a coordination system where weekly community governance directs HYDX emissions & protocol revenue. Value flows to where liquidity and volume are most productive, based on protocol alignment.

Hydrex

Hydrex ($HYDX) is experiencing a surge, with community members citing its potential as a competitor to $AERO and its recent launch on Base as a DUNA governed protocol. Discussions revolve around its locked tokenomics, community incentives, and economic safeguards, with some speculating about a potential Coinbase listing. Traders are actively sharing perspectives on social media, contributing to the increased attention and upward price movement.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending as Bitcoin flirts with all-time highs, sparking excitement about potential future gains. The community is actively discussing bullish scenarios, including predictions of substantial price increases and potential stimulus benefits. Broader market sentiment around Bitcoin and the influence of institutional investors are also key talking points.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter ($JUP) is trending as the community focuses on Solana-based meme coin $UPDOG, which is exclusively listed on Jupiter's strict list. Community members are actively promoting $UPDOG, highlighting its long-term development and potential for creating "UpDog millionaires" within the Solana ecosystem. Discussions also involve strategies for increasing $UPDOG's visibility and engagement within the broader crypto space.

National Storage Affiliates Trust operates as a real estate investment trust. It focuses on the ownership, operation, and acquisition of self-storage properties located within the metropolitan statistical areas throughout the United States. The company was founded by Arlen D. Nordhagen in April 2013 and is headquartered in Greenwood Village, CO.

National Storage Affiliates Trust

National Storage Affiliates is trending amid rating updates and price target adjustments from analysts, influencing community discussion. Some see it as a yield-focused investment, while others point to potential challenges due to high leverage and weaker real estate markets compared to peers like Extra Space and CubeSmart. Discussions also mention its dividend yield and potential resilience in a recession.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending amid discussions around potential tariff impacts, government shutdowns, and economic data manipulation. Community members are also weighing in on global relations and economic resilience. Additionally, various analyst ratings and price target adjustments for companies within the ETF are contributing to the ongoing conversation.

National Research Corp. engages in the provision of analytics and insights that facilitate patient, employee, and customer retention. It offers solutions that address specific needs around market insight, experience, transparency, and governance for healthcare providers, payers, and other healthcare organizations. The company was founded by Michael D. Hays in 1981 and is headquartered in Lincoln, NE.

National Research Corp

NRC is trending as the community discusses recent earnings, margin concerns, and risk factors. There is debate on whether the stock's oversold RSI signals a buying opportunity or further decline. Discussions also involve insider trading activity and the company's AI initiatives within the healthcare sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline 

Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -14.46% and -66.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up 

GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.

CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release

CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?  

KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors. 

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Kymera’s partnerships with Sanofi and Gilead drive value

Investing.com -- Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs. 

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive. 

Gilead Sciences, Inc. (GILD) said on Wednesday that it entered into an exclusive option and license agreement with biotech company Kymera Therapeutics, Inc. (KYMR) to accelerate the development and commercialization of a class of drugs with potential use in cancer treatment.The drugs belong to a class called molecular glue degrader (MGD), and they target cyclin-dependent kinase 2 (CDK2), a key contributor to tumor growth. CDK2-directed MGDs are a new type of drug designed to remove CDK2 rather than just inhibiting its function.The drugs have a broad oncology treatment potential, including in breast cancer and other solid tumors, the companies said.Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration.Kymera said that it will lead all research activities for the CDK2 program. If Gilead exercises its option to exclusively license the program, Gilead will have global rights to develop, manufacture, and commercialize all products resulting from the collaboration, the companies said.The transaction is expected to reduce Gilead’s full-year adjusted earnings per share by approximately $0.02 - $0.03. The company in April estimated adjusted and diluted EPS in the range of $7.70 and $8.10 for the full year.Both KYMR and GILD stock are down by 2% on Wednesday morning trading.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KYMR">KYMR</a> is trending in the ‘bearish’ territory, while sentiment around <a href="https://stocktwits.com/symbol/GILD">GILD</a> remained unchanged within ‘bullish’ territory.<figure class="image"><img style="aspect-ratio:625/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_25_at_9_58_39_AM_png_77702c2682.webp" alt="KYMR's Sentiment Meter and Message Volume as of 9:58 a.m. ET on June 25, 2025 | Source: Stocktwits" width="625" height="64"><figcaption>KYMR's Sentiment Meter and Message Volume as of 9:58 a.m. ET on June 25, 2025 | Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_25_at_9_59_13_AM_png_a30db31335.webp" alt="GILD's Sentiment Meter and Message Volume as of 9:59 a.m. ET on June 25, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>GILD's Sentiment Meter and Message Volume as of 9:59 a.m. ET on June 25, 2025 | Source: Stocktwits</figcaption></figure>KYMR shares have risen over 14% this year while GILD soared by about 14%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/ubs-sees-tesla-q2-deliveries-miss-wall-street-estimates/chmJjmARREi">UBS Sees Tesla Q2 Deliveries Miss Wall Street Estimates, But Sees Opportunity For Musk To Focus On Future Of EV Giant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Gilead Sciences logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit

Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.

Equity

Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.


Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Kymera Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

KYMR
Kymera Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KYMR News

KYMR Kymera Therapeutics Inc